What this page helps you do
Use this guide to prepare a child-specific hematology file in Nigeria, protect ongoing treatment while specialists consider HSCT, and plan guardian, visa and post-return arrangements before travel.
- Before hospital review
- Ask the child’s hematologist to identify the diagnosis, disease status, current treatment and the specific reason HSCT or a second opinion is being considered.
- Documents
- Include diagnosis-specific tests, treatment and transfusion history, recent organ-function and infection results, vaccination and medicine records, plus guardian authorization.
- Travel with a child
- Nigerian passport holders require a visa. Türkiye lists medical treatment and accompaniment as visa purposes and requires official parental approval for applicants under 18, subject to custody exceptions.
- Continuity of care
- Keep the Nigerian pediatric hematology team involved. Before travel, agree who will manage medicines, transfusion needs or acute events while review is pending and who will monitor immune recovery after return.
- No claim is made that HSCT is required for sickle-cell disease, leukemia or another diagnosis; a pediatric transplant team must decide.
- Exact visa documents, guardian consent formalities, stay length and travel fitness must be confirmed for the child’s circumstances.
Travel information checked 11 October 2026. Reconfirm requirements before booking.
Pediatric BMT Evaluation in Turkey from Nigeria
A parent or legal guardian in Nigeria may request a preliminary pediatric specialist review when the child’s treating team is considering HSCT or when the family needs a verified second opinion. Review before travel does not confirm treatment or admission.
Local Pediatric Care in Nigeria Remains Essential
Nigeria’s Federal Ministry of Health publishes national guidance for sickle-cell disease, and WHO guidance emphasizes continuing evidence-based pediatric care. An international HSCT review should complement—not interrupt—the child’s treating hematology plan.
An international review should complement—not interrupt—the child’s current care in Nigeria, especially when treatment or infection management is time-sensitive.
A Blood Disorder Does Not Automatically Mean Transplant
A diagnosis such as leukemia, thalassemia or sickle-cell disease does not by itself mean a child needs transplant. The pediatric hematology team must assess the exact condition, severity, treatment response, alternatives, risks and likely benefit.
Specialists may recommend chemotherapy, transfusion care, medicines, cellular therapy, observation or another approach depending on the case.
Acibadem Altunizade Pediatric Program
Official Acibadem sources connect Altunizade Hospital to adult and pediatric bone marrow transplantation and describe multiple cell-source approaches. It is the published campaign partner, not the only verified program available for comparison.
Potential Donor and HLA Assessment
A sibling, parent or other possible donor is not automatically suitable. HLA matching, donor health, consent, child safeguarding, cell source and any registry or legal requirements need separate specialist review.
Families should not arrange informal donor testing or travel based on assumptions. The transplant center defines the appropriate testing sequence.
Preparing the Child’s Records in Nigeria
Organize records around the clinical question and preserve original dates and findings.
- Pediatric hematology diagnosis, referral question and clinical course
- Hemoglobin electrophoresis or other diagnostic evidence when sickle-cell disease is relevant
- Bone-marrow, pathology, flow-cytometry, cytogenetic and molecular reports when relevant
- Treatment, transfusion, infection and complication history
- Recent blood counts and heart, lung, liver and kidney assessments available locally
- Vaccination and current medicine records
- Guardian identity, authorization and accompanying-adult details
- Available HLA or family-donor information only when requested by the transplant team
Parent or Legal-Guardian Submission
A parent or legally authorized guardian can submit the MedTransplant Case Review. The form records who is submitting, their relationship to the child and the authorization required for representation.
From Case Review to Pediatric Team Response
MedTransplant structures the available file and coordinates submission. The hospital may request pathology review, updated testing, HLA information or a pediatric consultation before deciding whether evaluation can progress.
Request Comparison with Other Verified Programs
Families may explore other verified pediatric programs or request comparison through MedTransplant. The comparison does not rank hospitals by unsupported claims and cannot guarantee acceptance.
Planning Travel from Nigeria with a Child
Travel should normally follow hospital feedback. Consider the child’s stability, guardian documents, who must accompany the child, requested tests, infection precautions, accommodation and expected stay.
Case-Specific Financial Planning
No unverified package price is presented. If review progresses, costs can depend on diagnostics, donor work-up, cell collection, conditioning, admission and the proposed treatment pathway.
Returning to Pediatric Care in Nigeria
Before any treatment, agree how the local pediatric hematology team and the transplant center will communicate about medicines, infections, blood counts, immune recovery, vaccination and urgent concerns.
Continue with the Acibadem Pediatric BMT Guide
Review the partner-program pathway, diagnostic boundaries, donor safeguards and parent or guardian submission process.
Explore pediatric BMT evaluation at Acibadem AltunizadeFrequently Asked Questions
Can a parent submit a child’s case from Nigeria?
Yes. A parent or legal guardian can identify their relationship and authorization in the MedTransplant Case Review.
Does leukemia always require bone marrow transplant?
No. Treatment depends on the leukemia type, risk features, response and available alternatives. Pediatric specialists decide whether HSCT should be considered.
Does thalassemia or sickle-cell disease always require transplant?
No. Severity, current treatment, complications, donor options, alternatives and individual risks all matter.
Is a sibling automatically a suitable donor?
No. HLA matching, health, consent, safeguarding and the proposed cell source require separate hospital-led assessment.
Can MedTransplant find a donor?
No. MedTransplant does not find, recruit, sell, broker or guarantee donors.
Does submission guarantee the child’s acceptance?
No. Submission guarantees neither diagnosis, hospital acceptance, donor approval, transplantation, timing nor outcome.
Can families compare another pediatric program?
Yes. Acibadem Altunizade is the published partner for this campaign, while families may explore other verified programs or request comparison.
When should the family book travel?
Usually after the hospital reviews the available file and describes the possible next assessment steps.
Sources and verification
- Acibadem Altunizade Hospital
- Acibadem Pediatric Bone Marrow Transplantation Unit
- NCI: Stem cell and bone marrow transplants
- NCI: Childhood acute lymphoblastic leukemia treatment
- NCI: Children with Cancer—A Guide for Parents
- Nigeria Federal Ministry of Health: National guideline for control and management of sickle cell disease
- WHO guideline: Management of sickle-cell disease in children and adolescents
- Türkiye Ministry of Foreign Affairs: General information about Turkish visas
- Turkish Embassy in Abuja: Visa requirements
Pediatric medical responsibility
MedTransplant coordinates parent- or guardian-led case preparation and referral. Pediatric specialists make all diagnostic, treatment, donor and acceptance decisions.
